Is BPC-157 Legal Right Now? What the July 2026 FDA Vote Changed

Last verified: 20 August 2026

That last point is the one almost every consumer page gets backwards. Vendors read "removed from the do-not-compound list" as a green light. The mechanism of the removal was the opposite of a green light, and the difference is the whole story.

Below is the actual sequence, with the primary documents. There are four gates between BPC-157 and lawful availability. One of them moved in 2026. Three did not.

The four gates, at a glance

What actually makes compounding lawful — and why "Category" is not the law

Compounding pharmacies operating under section 503A of the Federal Food, Drug, and Cosmetic Act may use a bulk drug substance only if it clears one of three statutory conditions. 21 U.S.C. 353a(b)(1)(A)(i) permits a bulk substance that:

1. complies with the standards of an applicable USP or NF monograph, or
2. is a component of a drug approved by the Secretary, or
3. appears on the 503A Bulks List, which FDA develops through rulemaking.

Fail all three and the substance cannot lawfully be used in 503A compounding. There is no fourth route, no clinical-judgment exception, and no prescription that cures the defect.

BPC-157 fails all three. There is no USP or NF monograph for it. It is not a component of any FDA-approved drug. And the 503A Bulks List — the real one, codified at 21 CFR 216.23 — contains six substances: brilliant blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester, and thymol iodide. Four of the six are topical. None is a peptide. The regulation was last amended on 19 February 2019 and has not been touched since.

Everything else you have read about "categories" sits outside that statute. Categories 1, 2 and 3 are an interim enforcement-discretion policy FDA created to triage nominated substances while it works through them. FDA's own page (updated 14 May 2026) is careful about what each tier means:

• Category 1 — nominated with sufficient information, no identified safety problem. FDA says it "does not intend to take action" against a compounder using the substance, provided the conditions in its interim policy guidance are met: a section 510-registered manufacturer, a valid certificate of analysis, and all other 503A conditions.
• Category 2 — FDA has identified significant safety risks. FDA "would consider taking action against a compounder."
• Category 3 — nominated without enough information to evaluate. Practical effect is the same as Category 2.
• No category at all — the substance sits outside the framework. Enforcement discretion attaches only to Category 1, so a substance in no category gets none of it.

Category 1 is not lawfulness either. It is a published statement that FDA does not currently plan to act. That is worth something to a pharmacy assessing risk. It is not a legal authorization, and it can be withdrawn.

Gate 1: the April 2026 removal, and why it was not a win

On 15 April 2026, FDA republished its interim 503A list with twelve peptides removed from Category 2, BPC-157 among them. Coverage of that action — and a great deal of vendor copy written since — treated it as FDA lifting a ban.

It was not. The removals happened because the nominators withdrew the nominations. FDA did not evaluate these substances and clear them. The parties who had asked for them to be considered took the requests back, and FDA took them off the risk list accordingly. Frier Levitt put it in one sentence:

"Removal from Category 2 does not render these bulk drug substances eligible for compounding under section 503A."

Hyman, Phelps & McNamara's FDA Law Blog made the sharper version of the point: these peptides "were never on 'Category 1'" and so "could not be legally used in compounding" beforehand either. Nothing was restored, because nothing had been granted.

The counterintuitive part, and the part that inverts the vendor framing entirely: a withdrawn nomination is a worse position than Category 2. A Category 2 substance is at least inside the framework, with a live nomination and a path to reconsideration. A substance with no category is outside it. There is no pending request, no enforcement discretion, and no procedural momentum. FDA's category list dated 14 May 2026 shows BPC-157 in no category. Of the twelve peptides removed in April, exactly one landed in Category 1: GHK-Cu, and only for non-injectable routes. Sheppard Mullin confirms that reading — only GHK-Cu was recategorized, and the rest "currently exist in a regulatory gray zone."

One honest ambiguity is worth naming rather than smoothing over. Dropping the "significant safety risk" designation plausibly makes FDA enforcement less likely in practice, because that designation was the clearest justification for acting. Less likely to be enforced against is not the same as lawful. Vendors have collapsed those two things deliberately.

Gate 2: the 23–24 July 2026 PCAC vote

The Pharmacy Compounding Advisory Committee met at FDA's White Oak campus on 23 and 24 July 2026 to consider seven peptides for the 503A Bulks List. BPC-157 was nominated for ulcerative colitis — not for tendon repair, joint pain, or gut health, which is what it is actually marketed for.

Six of seven were recommended. Tallies agree across McDermott, FDA Law Blog and Lumalex.

Two things about that vote were left out of the coverage that reached consumers.

First, it is advisory and non-binding. PCAC recommends; it does not legislate. The 503A Bulks List is amended by rulemaking, not by a show of hands. Holland & Knight, writing on 4 August 2026, was blunt: because the recommendations are nonbinding, "they did not result in any change in law," and "these peptides still cannot be lawfully compounded."

Second, the committee voted against its own agency's scientists. FDA's multidisciplinary review team, in the briefing document prepared for the meeting, recommended not including any of the substance variants under discussion. The committee overrode that on six of seven. FDA's BPC-157 review is the most complete synthesis of the human evidence that exists, and it concluded there is "insufficient clinical safety information to characterize the safety profile of BPC-157" and that reviewers found "no studies that administered BPC-157 to humans via the proposed oral, SC, nasal, or transdermal route of administration." The only controlled human trial used a rectal enema for ulcerative colitis and did not meet its endpoint.

The panel itself also drew scrutiny. AJMC reported that the reconstituted roster "included more practitioners who prescribe or produce peptides than historical rosters." We report that as reported; we have not independently audited the roster.

Gate 3: rulemaking has not started

This is the gate that determines when, if ever, the answer changes — and it is exactly where nothing is happening.

To add BPC-157 to the 503A Bulks List, FDA must run notice-and-comment rulemaking: publish a proposed rule in the Federal Register, take public comment, respond to it, publish a final rule, and let it take effect. As of today there is no proposed rule. Buchanan Ingersoll & Rooney, writing on 18 August 2026 — two days ago, and the most recent legal analysis we located — states that the votes "did not amend the 503A Bulks List," that "there is no fixed statutory deadline within which FDA must publish a proposed or final rule," and that pharmacies:

"should not interpret the favorable votes as authorization to begin compounding."

The historical comparator is not encouraging for anyone waiting. The analogous cycle ran from a December 2016 advisory committee to a February 2019 final rule — over two years. That February 2019 rule is the last time 21 CFR 216.23 was amended at all.

There is a faster path FDA floated at the meeting: rather than waiting for rulemaking, it could move recommended peptides onto the interim Category 1 list with conditions attached, potentially including adverse-event reporting and testing requirements (FDA Law Blog). That has not happened. If it does, it would be enforcement discretion — a statement that FDA does not intend to act — not lawfulness. Worth watching, because it could happen with little warning and would materially change the practical answer without changing the legal one.

Gate 4: none of this means approved, and none of it means effective

Legality and evidence are independent axes. Conflating them is the error the entire category makes, in both directions.

Suppose FDA completed rulemaking tomorrow and BPC-157 appeared at 21 CFR 216.23. That would make it a bulk substance a 503A pharmacy may lawfully compound. It would not make it an FDA-approved drug, would not mean anyone had reviewed it for safety and effectiveness the way approval requires, and would not generate one additional human study.

The evidence base is where FDA's reviewers found it. STAT reported in February 2026 that of roughly 200 published BPC-157 studies, nearly all include one of two researchers among the authors, and that a Polish review team warned this concentration "could lead to confirmation bias." The human record consists of an unpublished trial, a 2015 trial whose data were withdrawn before external review, and three uncontrolled studies of between two and sixteen participants. A University of Utah chief medical resident quoted in the same piece said BPC-157 "should not be used by humans." FDA reviewers described the peptide studies before them as short in duration, small in sample size, and insufficient to establish safety or effectiveness.

We describe what BPC-157 is marketed for. We do not tell you it works, because on the published record nobody can substantiate that.

What this means if you want BPC-157 today

Route one: a prescriber

You can find a telehealth company or clinic that will sell you compounded BPC-157 this afternoon. That is a fact about the market, not about the law, and worth knowing before you spend the money.

The legal defect is in the bulk substance, not in your prescription. A valid prescription is necessary for compounding and nowhere near sufficient; no prescriber can authorize a pharmacy to use a bulk substance that fails all three statutory conditions. Holland & Knight's summary stands: FDA "can continue to take enforcement action." FDA has published specific guidance for telehealth companies promoting compounded drugs, which is a reasonable indication of where its attention sits.

Where the risk actually lands matters. The legal exposure sits primarily with the pharmacy and the prescriber, not with you. We found no record of FDA enforcement against an individual patient. Your exposure is clinical and financial: an injectable product whose purity, potency and impurity profile nobody has verified, with no adverse-event infrastructure behind it. FDA's review noted that certificates of analysis submitted for these peptides lacked testing for aggregates, endotoxins and individual impurities — the specific gaps that drive immunogenicity risk in injected peptides. It also noted that BPC-157 free base is stable only around three weeks at room temperature and needs storage below minus 18 degrees Celsius. Products shipped without a cold chain are a real question, not a hypothetical one.

Route two: the "research use only" grey market

The websites selling BPC-157 vials stamped "research use only, not for human consumption" are relying on a disclaimer FDA has already rejected in writing. Intended use is determined by the totality of the evidence, including the marketing copy on the seller's own site, under 21 CFR 201.128.

On 31 March 2026, FDA sent letters to seven "research use only" peptide sellers saying so directly:

"Despite statements on your product labeling marketing your products for 'Research Use Only,' evidence obtained from your website establishes that your products are intended to be drugs for human use."

The formulation is not a one-off. FDA's 17 June 2026 warning letter to Wholesale Peptide repeats it almost verbatim, and one of the 31 March letters went to Gram Peptides. The violations charged are introduction of unapproved new drugs into interstate commerce. We do not link to grey-market peptide sellers, so you will not find one on this page.

The second problem is that you have no idea what is in the vial. Matthew Fedoruk of the U.S. Anti-Doping Agency has put it more bluntly than any regulator:

"It could be a peptide. It could be a steroid. It could be something just like water."

We looked for a peer-reviewed independent purity survey of grey-market peptides and could not find one. Every result was vendor-published testing or affiliate marketing dressed as testing. We are not citing those.

Anti-doping and the military: a separate axis again

BPC-157 is prohibited in sport at all times. It is named in WADA category S0, non-approved substances, which covers any pharmacological substance with no current approval by any governmental health authority for human therapeutic use (S0 definition). USADA's page on BPC-157 states there are "no human clinical trials establishing efficacy for the use of BPC-157 for any diagnosis or treatment," and that "it is unknown if there is a safe dose, or if there is any way to use this substance safely."

Service members have a separate problem: BPC-157 appears on the Department of Defense Prohibited Dietary Supplement Ingredients List, and DoD's Operation Supplement Safety maintains a page on it. If you are tested — in sport or in uniform — read those two pages before anything on a vendor site.

This axis moves independently of legality: sermorelin and tesamorelin are prohibited in sport even where legitimately prescribed, and a future rule adding BPC-157 to the bulks list would not change its WADA status.

What would have to happen, and when

1. FDA reviews the docket. The agency said it would analyze the full record, including post-meeting submissions, before deciding anything. Docket FDA-2025-N-6895 closed on 22 July 2026.
2. Either an interim move or a proposed rule. FDA could place recommended peptides in Category 1 with conditions — faster, but enforcement discretion only. Or it publishes a proposed rule in the Federal Register, which starts the real clock.
3. Comment period and response. Months, and contested. FDA's own scientists recommended rejection; that disagreement does not disappear because a committee voted the other way.
4. Final rule, then effective date. Only at that point does 21 CFR 216.23 change.

A realistic floor, if FDA moved promptly and nothing was contested, is well into 2027. The only comparable cycle took over two years, and no statutory deadline forces FDA to move at all. Anyone giving you a date is guessing. We will update this page when the Federal Register says otherwise.

Where the record is thin, and we are not going to pretend otherwise

Three gaps are worth stating plainly, because other pages paper over them.

FDA published no Federal Register notice for the April action. The removal was made by republishing a web page. A Federal Register notice did publish on 16 April 2026 — document 2026-07361 — but it announced the PCAC meetings, not the removals. That means the April action has no citable primary instrument, which is unusual and which is why the details are contested.

The count is disputed. Frier Levitt and Orrick report twelve peptides removed. National Law Review, on 22 April 2026, describes seven. With no Federal Register notice to check either against, we cannot resolve it. It does not change BPC-157's status — every account includes BPC-157 — but it is a fair measure of how thin the documentary record is.

FDA has not posted PCAC minutes. The meeting page was last updated on 6 August 2026 without them. Every vote tally on this page is therefore trade-press sourced, from legal analysts who attended. They agree with each other, which is reassuring but not the same as an official record. AJMC's report of the Emideltide vote is internally inconsistent — it describes a 7-to-6 tally as a rejection, which cannot be right; the two legal sources report 6 for, 7 against, 1 abstaining, which is coherent. We have used the legal sources.

If FDA posts minutes that contradict any figure here, we will correct it and say so.

Frequently asked questions

Did RFK make peptides legal?

No. Nothing announced in 2026 by HHS or FDA has made BPC-157 or any of the other peptides in this group lawful to compound. The April 2026 action was a removal from an interim risk list, triggered by nominators withdrawing their nominations, with no Federal Register notice and no change to 21 CFR 216.23. The regulation that actually governs has been unchanged since 19 February 2019. This claim circulates widely and it is false. One example of how far the confusion spread into professional media: Pharmacy Times published a piece stating that roughly 14 of 19 peptides moved to Category 1 and naming thymosin alpha-1, CJC-1295 and ipamorelin among them. FDA's own category list contradicts that: CJC-1295 and thymosin alpha-1 sit in the withdrawn-nomination table, and ipamorelin acetate remains in Category 2.

Can my doctor prescribe BPC-157?

A licensed prescriber can write a prescription for almost anything. The question is whether a pharmacy can lawfully fill it, and for BPC-157 the answer is no, because the bulk substance fails all three conditions in 21 U.S.C. 353a(b)(1)(A)(i). The defect is in the ingredient, not the prescription. Clinics and pharmacies do dispense it anyway; that is a description of the market, not a legal opinion.

When will BPC-157 be available legally?

Unknown, and not soon. FDA must complete notice-and-comment rulemaking, which has not started. There is no statutory deadline. The one comparable cycle took over two years. The faster scenario is an interim Category 1 placement with conditions, which FDA raised as a possibility at the July meeting and has not acted on — and which would be enforcement discretion, not legality.

Is BPC-157 legal to buy for research?

The "research use only" label does not do what sellers imply. FDA determines intended use from the totality of the evidence, including website copy, and has said in writing that the disclaimer does not survive marketing aimed at human users. That exposure falls on sellers, who have received warning letters charging introduction of unapproved new drugs into interstate commerce. We found no record of FDA enforcement against an individual buyer. Your practical risk is not prosecution; it is that the vial's contents are unverified, that injected peptides from untested sources carry immunogenicity risk FDA has specifically flagged, and that if you are tested in sport or in the military, BPC-157 is prohibited.

Was BPC-157 approved by the FDA in July 2026?

No. The July 2026 vote was an advisory committee recommendation about adding a bulk substance to a compounding list. It was not a drug approval, was not binding, and was taken over FDA staff's recommendation to reject. BPC-157 has never been an FDA-approved drug.

Is it different if it's oral, nasal, or a cream instead of an injection?

Not legally. The statutory analysis is about the bulk substance, not the dosage form. On the evidence side, FDA's reviewers reported finding no human studies of BPC-157 by the oral, subcutaneous, nasal or transdermal routes at all.

This is consumer research about how peptides are regulated and sold. It is not medical advice, and we are not your doctor. Nothing here should be used to start, stop or change any treatment. Talk to a licensed clinician who knows your history.